Carcinogenicity studies are generally required for pharmaceuticals that are expected to be used continuously for at least six months or intermittently for the treatment of chronic or recurrent conditions. The objectives of carcinogenicity studies are to identify a tumorigenic potential in animals and to assess the relevant risk in humans.